Tenet Healthcare Corporation delivered strong full-year 2025 results, with net operating revenues reaching $21.3 billion and consolidated adjusted EBITDA growing 14% to $4.566 billion, resulting in a 210 basis point improvement in margins to 21.4%. The performance was driven by robust same-store revenue growth, high patient acuity, and disciplined cost control across both the Hospital and USPI segments, with USPI EBITDA growing 12% to $2.026 billion and Hospital EBITDA growing 16% to $2.54 billion. The company generated $2.53 billion in free cash flow, significantly deleveraging the balance sheet to 2.25x EBITDA, and repurchased approximately 22% of outstanding shares since 2022. Looking to 2026, management projects adjusted EBITDA of $4.485 billion to $4.785 billion, representing roughly 10% core growth excluding headwinds, though they face a $250 million impact from the expiration of enhanced exchange premium tax credits.
| Metric | Value | Change |
|---|---|---|
| 2025 Net Operating Revenues | $21.3 billion | N/A |
| 2025 Consolidated Adj. EBITDA | $4.566 billion | +14% |
| 2025 Adj. EBITDA Margin | 21.4% | +210 bps |
| Q4 2025 Net Operating Revenues | $5.5 billion | N/A |
| Q4 2025 Consolidated Adj. EBITDA | $1.183 billion | +13% |
| USPI 2025 Adj. EBITDA | $2.026 billion | +12% |
| Hospital 2025 Adj. EBITDA | $2.54 billion | +16% |
| 2025 Free Cash Flow | $2.53 billion | N/A |
| Leverage Ratio (Dec 31, 2025) | 2.25x | N/A |
| Shares Repurchased (2025) | 8.8 million | N/A |
Tenet is aggressively leveraging its strong free cash flow generation ($2.53 billion in 2025) for shareholder returns, having retired approximately 22% of its outstanding shares since 2022. Management explicitly stated they will 'continue to deploy capital for share repurchase, particularly at our current valuation multiples,' signaling a belief that the stock is undervalued. This capital return strategy is supported by a deleveraged balance sheet (2.25x EBITDA) and significant cash on hand ($2.88 billion), allowing them to buy back stock while still investing in growth.
The USPI segment remains a primary growth engine, delivering 12% EBITDA growth and 7.5% same-facility revenue growth, well above their long-term target of 3-6%. Management highlighted 'double-digit same-store volume growth in total joint replacements' and invested nearly $350 million in M&A and de novo activity, adding 35 facilities. The strategic focus remains on shifting services to lower-cost sites of care, with the phase-out of the inpatient-only list in 2026 expected to provide a 'gradual tailwind' for high-acuity spine and urology procedures.
Management is shifting from traditional annual expense management to 'structural' cost reductions utilizing technology, AI, and automation. Saumya Sutaria emphasized this involves 'the application of those technologies in our global business center' and 'clinical throughput,' such as length of stay management and OR efficiency. This initiative is designed to be sustainable and modern, positioning the company to maintain margin expansion even as they face reimbursement headwinds in 2026 and beyond.
The completed Conifer transaction with CommonSpirit was highlighted as a significant financial success, generating over $1 billion in after-tax NPV. By retiring $885 million in obligations and receiving $540 million in equity plus $1.9 billion in accelerated cash flow, Tenet has secured 'complete control of the strategic future of Conifer.' This move reduces complexity on the balance sheet and provides resources to redeploy talent toward growth opportunities starting in 2027.
Tenet is successfully driving revenue growth through acuity and payer mix rather than just volume. Same-hospital revenue per adjusted admission increased 5.3%, and USPI saw net revenue per case rise 5.5%. Management attributes this to 'high patient acuity' and 'favorable payer mix,' suggesting their strategy of focusing on higher-acuity service lines and physician recruitment is effectively capturing more complex, profitable cases.
The expiration of the enhanced premium tax credits on the exchange marketplace represents a significant $250 million headwind to 2026 EBITDA. Management is assuming a '20% reduction in overall enrollment' and acknowledges 'uncertainty regarding effectuation rates' as patients decide if they can afford premiums. This creates a wide range of potential outcomes for the year and adds substantial risk to the volume outlook for the Hospital segment.
Fourth-quarter hospital volumes showed signs of softness, with same-hospital inpatient adjusted admissions remaining flat. Management attributed this to a 'respiratory season [that] was probably a little weaker than otherwise might have expected.' While revenue per admission grew, the lack of volume growth raises concerns about the underlying demand trends and the sustainability of admission growth guidance of 1-2% for 2026.
The Conifer business will face a revenue headwind as the service agreement with CommonSpirit concludes at the end of 2026. While management has plans to redeploy resources and reduce costs, the loss of this contract creates a transition risk. Management noted they are not expecting cost reductions in 2026 and may even see increased costs related to transition services, pressuring margins in the interim.
Guidance for 2026 includes a $148 million benefit from prior-year supplemental Medicaid payments that occurred in 2025, which will not repeat. Additionally, while there is a $40 million favorable revenue adjustment in 2026 from the Conifer transaction, the comparison against the prior year's elevated Medicaid payments creates a difficult year-over-year hurdle rate that could obscure underlying operational performance.
Management's guidance for 2026 implies a significant deceleration in growth compared to 2025 (14% EBITDA growth vs. ~10% core growth in 2026 excluding headwinds). While the exchange headwind is known, the reliance on 'structural' cost savings and technology implementation to bridge the gap introduces execution risk, especially as these initiatives are still ramping up.
Overall: Management exhibited a high level of confidence and discipline throughout the call, emphasizing a 'multiyear track record' of execution and margin expansion. They were assertive regarding their capital allocation priorities, particularly share repurchases, and detailed in explaining the 'structural' nature of their new cost efficiency initiatives involving AI and automation. While acknowledging the uncertainty around government subsidies, their tone remained resolute in their ability to achieve core growth targets.
Confidence: HIGH - Management consistently exceeded expectations in 2025, provided specific guidance for 2026 despite macro headwinds, and spoke with certainty about their operational improvements and the value of the Conifer transaction.
$21.5 billion - $22.3 billion
$4.485 billion - $4.785 billion
$2.13 billion - $2.23 billion
$2.355 billion - $2.555 billion
$2.5 billion - $2.8 billion
1% - 2%
3% - 6%
Hedging & Uncertainty: Management employed hedging language primarily around the external macro factors, specifically the expiration of exchange subsidies. Phrases like 'wide range of potential outcomes,' 'conservatively taken these matters,' and 'uncertainty regarding effectuation rates' were used to set expectations for the 2026 guidance. However, regarding internal operations, the language was assertive and specific, using terms like 'structural,' 'tackling,' and 'confident' to describe their cost initiatives and growth plans. This contrast suggests management feels in control of operations but is rightfully cautious about policy impacts they cannot influence.
We are tackling expense management more structurally... looking more thoroughly at the deployment of technology. - Saumya Sutaria, Chairman and CEO
We recognize the uncertainty regarding effectuation rates... and have conservatively taken these matters into our initial guidance. - Saumya Sutaria, Chairman and CEO
We remain the preferred acquirer and developer of assets in this space. - Saumya Sutaria, Chairman and CEO
We expect to continue to deploy capital for share repurchase, particularly at our current valuation multiples. - Saumya Sutaria, Chairman and CEO
The incremental value from actually running out the contract... after-tax present value was north of a billion dollars. - Saumya Sutaria, Chairman and CEO
We are confident in our ability to deliver on our outlook for 2026 and continue to drive value for patients, physician partners, and shareholders. - Sun Park, EVP and CFO
Analyst Sentiment: Analysts were highly focused on the sustainability of the company's growth margins and the specific mechanics of the exchange subsidy headwind. Questions probed deeply into the 'structural' nature of cost cuts and whether the 10% core growth guidance was replicable in future years.
Management Responses: Management responses were detailed and transparent, particularly regarding the assumptions built into the guidance (e.g., 20% enrollment drop on exchanges). They defended the sustainability of their margin expansion by pointing to technology investments and standardization of processes.
Analysts sought clarification on the 'structural' expense management, asking if the efficiency gains from AI and automation were one-time events or sustainable long-term improvements.
There was significant discussion regarding the impact of the expiring enhanced premium tax credits, with analysts asking for specifics on enrollment assumptions and the potential for patients to shift to commercial plans.
Questions addressed the softness in Q4 hospital volumes, with management explaining it was due to a weaker respiratory season than expected.
The Conifer transaction was a major topic, with analysts asking about the redeployment of resources and the financial mechanics of the deal.
Tenet Healthcare is demonstrating exceptional operational discipline, achieving 14% EBITDA growth and significant margin expansion in 2025. The company has successfully transformed its portfolio, with USPI serving as a high-growth engine and the Hospital segment delivering robust profitability through acuity management and cost control. The aggressive share repurchase program (22% of shares retired) signals strong confidence in intrinsic value. While the $250 million headwind from expiring exchange subsidies creates near-term uncertainty, the underlying core business is growing at a double-digit clip (~10% core growth guidance). The strategic use of AI and automation for 'structural' cost reductions and the financial success of the Conifer transaction provide multiple levers for future value creation. Given the strong free cash flow generation, deleveraged balance sheet, and attractive valuation, the risk/reward profile remains favorable.
The expiration of the enhanced premium tax credits is creating a $250 million headwind for Tenet, with management assuming a 20% drop in enrollment. This highlights the vulnerability of hospital revenues to government subsidy changes and the potential for increased uninsured rates.
Tenet reported a 110 basis point improvement in salary, wages, and benefits as a percentage of revenue (40.2%), with contract labor remaining low at 2.1%. This indicates that the labor cost inflation plaguing the sector is stabilizing or being effectively managed.
Tenet invested $350 million in M&A and de novo activity in 2025, adding 35 facilities. Management stated they remain the 'preferred acquirer' and see a 'strong pipeline,' suggesting capital is available and assets are flowing to strong operators.
Management noted uncertainty regarding 'effectuation rates,' questioning if consumers will actually pay their premiums once subsidies expire. This reflects broader economic stress on consumers and potential elasticity in healthcare demand.